BGNE241220C300000
- 0.00
- 0.000.00%
BeiGene Newsroom
BeiGene Announces U.S. Regulatory Filing
Labcorp Holdings Names Julia Wang Chief Financial Officer, Effective Dec. 2 >LH
Press Release: Labcorp CFO Glenn Eisenberg Announces Plans to Retire
BeiGene Has Entered Into A Settlement Agreement With MSN Pharmaceuticals And MSN Laboratories Private Resolving Patent Litigation Related To MSN's Abbreviated New Drug Application Seeking Approval To Market A Generic Version Of Brukinsa (Zanubrutinib)...
Express News | Beigene Ltd: Agreement Provides for Generic Entry of Innovative Btk Inhibitor in 2037
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
Express News | Beigene Announces Settlement of Litigation Against Generic Filer of Brukinsa
BeiGene Canada Announces Inaugural Grant Recipients at New Brunswick's Health Research Symposium
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
How do foreign investors adjust their positions in Chinese stocks? Alibaba and jd.com frequently appear, while Buffett builds a position that boosts a Hong Kong stock.
① The 13F quarterly reports for US stocks have been released. How are Wall Street institutions adjusting their positions on Chinese stocks? ② Buffett's investment in domino's is boosting a Hong Kong stock. What are the highlights?
China Data Point to Gradual Improvement, but Tariff Risk Looms
bocom intl: Raised beigene's target price to 159 Hong Kong dollars, with product sales and operation continuing to improve in Q3.
Bocom Intl released a research report stating that it has raised the target price of Beigene (06160) to 159 Hong Kong dollars, based on the 3Q performance and the continued strong trend in product sales volume, raising the revenue forecast for 2024-26 by 6-7%. At the same time, the peak sales forecast for Zejula is raised by 4% to 5.4 billion. The bank stated that in the next 12 months, they will focus on: 1) approval of more indications such as LESC, LGC, etc. for Tislelizumab in core developed countries like Europe and America, data readouts of I/O combination therapy (Tislelizumab in combination with OX40, LAG3, etc.); 2) Bcl-2 inhibitors.
【Brokerage Focus】bocom intl raised the target price for beigene (06160), stating that product sales and operation continue to improve in Q3 2024.
Jingu News | bocom intl issued research reports, pointing out that Beigene(06160) 3Q24 total revenue increased by 28.2% year-on-year to 1.002 billion (USD, the same below), including product revenue of 0.993 billion (+66.9% year-on-year), mainly including: 1) Global sales of Zejula amounting to 0.69 billion (MOM +8.3%/YOY +93.0%), with USA accounting for 0.504 billion (MOM -12.2%/YOY +62.3%), the main reason for the slowdown in MOM growth rate is the seasonal fluctuations brought by 3Q holidays in Europe and America, coupled with the high base effect caused by the one-time drug purchase of 15 million at the end of 2Q. 2
Beigene intends to change its English name to "BeOne Medicines Ltd."
Beigene (06160) announced that, for the purpose of continuity, the board of directors proposed to change the company's English name from "BeiGene, Ltd." to "BeOne Medicines Ltd." and adopted the proposed Swiss articles of association including the proposed company's English name change. The Chinese name of the company will remain unchanged. The announcement stated that the new English name highlights the company's commitment to developing innovative drugs, as well as eliminating cancer by working with various sectors globally to serve more patients. The board of directors believes that the proposed change of the company's English name is in the overall interest of the company and shareholders.
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.
Sector Update: Health Care Stocks Advance Pre-Bell Thursday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Powell Speech
BeiGene Proposes Name Change
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Express News | Beigene Ltd : BofA Global Research Cuts Price Objective to $207 From $209